Table 1.
Clinical and pre-clinical studies in coronavirus disease 2019 and pancreatic cancer
|
Disease
|
Antibody/drug
|
Target
|
Title
|
ClinicalTrials.gov identifier
|
Ref.
|
| COVID-19 | Tocilizumab | IL-6 receptor | Efficacy of Tocilizumab on Patients With COVID-19 | NCT04356937 | [75] |
| COVID-19 | Tocilizumab | IL-6 receptor | A Study to Investigate Intravenous Tocilizumab in Participants with Moderate to Severe COVID-19 Pneumonia | NCT04363736 | [76,77] |
| COVID-19 | Tocilizumab | IL-6 receptor | RECOVERY Trial: Open-Label RCT of Tocilizumab and Usual Care in Hospitalized Patients With COVID-19 | NCT04381936 | [78,79] |
| COVID-19 | Sarilumab | IL-6 receptor | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | NCT04315298 | [80,81] |
| COVID-19 | Sarilumab | IL-6 receptor | Sarilumab COVID-19 | NCT04327388 | [82] |
| COVID-19 | Siltuximab | IL-6 | An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications (SISCO) | NCT04322188 | [83] |
| COVID-19 | Siltuximab | IL-6 | Treatment of COVID-19 Patients with Anti-interleukin Drugs (COV-AID) | NCT04330638 | [84] |
| COVID-19 | Clazakizumab | IL-6 | Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients with Life-threatening COVID-19 Infection | NCT04381052 | None |
| COVID-19 | Clazakizumab | IL-6 | Clazakizumab (Anti-IL-6 Monoclonal) Compared to Placebo for COVID-19 | NCT04348500 | None |
| COVID-19 | Clazakizumab | IL-6 | A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients with Life-threatening COVID-19 Infection | NCT04343989 | None |
| COVID-19 | Furosemide | IL-6 and TNF-α | Furosemide as Supportive Therapy for COVID-19 Respiratory Failure | NCT04588792 | [72] |
| COVID-19 | BMS-986253 | IL-8 | Anti-IL-8 for Patients With COVID-19 | NCT04347226 | None |
| Pancreatic cancer | Siltuximab | IL-6 | Siltuximab and Spartalizumab in Patients with Metastatic Pancreatic Cancer | NCT04191421 | None |
| Pancreatic cancer | Bazedoxifene | IL-6 | Bazedoxifene as a Concomitant Treatment of Patients with Metastatic Pancreatic Adenocarcinoma (BAZE) | NCT04812808 | None |
| Pancreatic cancer | Bazedoxifene and Navarixin (SCH527123) | IL-6 and IL-8 | Blocking IL-6 and IL-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells | Pre-clinical research | None |
| Pancreatic cancer | Antibody | IL-6 and PD-L1 | IL-6 and PD-L1 antibody blockade combination therapy reduces tumor progression in murine models of pancreatic cancer | Pre-clinical research | None |
| Pancreatic cancer | Oncolytic vaccinia virus armed with IL-10 | IL-10 | A new role of IL-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for the treatment of pancreatic cancer | Pre-clinical research | None |
COVID-19: Coronavirus disease 2019; IL: Interleukin; TNF: Tumor necrosis factor; PD-L1: Programmed death 1.